COVID-19 and the CHADS-VASc Score: Is It Time to Refine?
作者信息
Salabei Joshua K
机构信息
University of Central Florida College of Medicine, Graduate Medical Education / North Florida Regional Medical Center, Internal Medicine Residency Program, Gainesville, Florida
出版信息
Clin Med Res. 2021 Dec;19(4):159-160. doi: 10.3121/cmr.2021.1701.
Abstract
摘要
相似文献
1
COVID-19 and the CHADS-VASc Score: Is It Time to Refine?新冠病毒肺炎与CHADS-VASc评分：是时候进行优化了吗？
Clin Med Res. 2021 Dec;19(4):159-160. doi: 10.3121/cmr.2021.1701.
2
The ATRIA score is superior to the m-CHA2DS2-Vasc score in predicting in-hospital mortality in COVID-19.ATRIA 评分优于 m-CHA2DS2-Vasc 评分，可预测 COVID-19 患者住院期间的死亡率。
Rev Assoc Med Bras (1992). 2021 Mar;67(3):443-448. doi: 10.1590/1806-9282.20200983.
3
Meta-analysis of CHADS2 versus CHA2DS2-VASc for predicting stroke and thromboembolism in atrial fibrillation patients independent of anticoagulation.CHADS2与CHA2DS2-VASc对心房颤动患者独立于抗凝治疗的中风和血栓栓塞预测的荟萃分析。
Tex Heart Inst J. 2015 Feb 1;42(1):6-15. doi: 10.14503/THIJ-14-4353. eCollection 2015 Feb.
4
Comparison of CHADS2 and CHA2DS2-VASC anticoagulation recommendations: evaluation in a cohort of atrial fibrillation ablation patients.CHA2DS2-VASC 与 CHADS2 抗凝推荐的比较：在房颤消融患者队列中的评估。
Europace. 2014 Feb;16(2):195-201. doi: 10.1093/europace/eut244. Epub 2013 Sep 12.
5
The impact of risk score (CHADS2 versus CHA2DS2-VASc) on long-term outcomes after atrial fibrillation ablation.风险评分（CHADS2与CHA2DS2-VASc）对心房颤动消融术后长期预后的影响。
Heart Rhythm. 2015 Apr;12(4):681-6. doi: 10.1016/j.hrthm.2014.12.034. Epub 2014 Dec 26.
6
Evaluation of Adherence to Guideline-Directed Antithrombotic Therapy for Atrial Fibrillation at Hospital Discharge.出院时房颤患者遵循指南指导的抗栓治疗情况评估。
J Cardiovasc Pharmacol Ther. 2018 Nov;23(6):502-508. doi: 10.1177/1074248418778804. Epub 2018 May 27.
7
[The thromboembolism risk of low-risk atrial fibrillation patients with different clinical characteristics].[不同临床特征的低风险心房颤动患者的血栓栓塞风险]
Zhonghua Xin Xue Guan Bing Za Zhi. 2020 Sep 24;48(9):735-739. doi: 10.3760/cma.j.cn112148-20200306-00164.
8
Oral anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1: a current opinion of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Council on Stroke.非瓣膜性心房颤动且 CHA2DS2-VASc 评分为 1 分的患者的口服抗凝治疗：欧洲心脏病学会心血管药物治疗工作组和欧洲心脏病学会卒中委员会的当前观点。
Eur Heart J Cardiovasc Pharmacother. 2019 Jul 1;5(3):171-180. doi: 10.1093/ehjcvp/pvz016.
9
Should atrial fibrillation patients with 1 additional risk factor of the CHA2DS2-VASc score (beyond sex) receive oral anticoagulation?对于 CHA2DS2-VASc 评分（除性别以外）有 1 个额外危险因素的房颤患者，是否应接受口服抗凝治疗？
J Am Coll Cardiol. 2015 Feb 24;65(7):635-42. doi: 10.1016/j.jacc.2014.11.046.
10
The CHA2DS2-VASc score and in-hospital mortality in patients with COVID-19: A multicenter retrospective cohort study.COVID-19患者的CHA2DS2-VASc评分与住院死亡率：一项多中心回顾性队列研究
Turk Kardiyol Dern Ars. 2020 Oct;48(7):656-663. doi: 10.5543/tkda.2020.03488.
引用本文的文献
1
COVID-19-Induced Complete Heart Block: Case Series and Literature Review.新冠病毒感染所致完全性心脏传导阻滞：病例系列与文献综述
Cureus. 2023 Apr 13;15(4):e37517. doi: 10.7759/cureus.37517. eCollection 2023 Apr.
2
COVID-19 and the cardiovascular system: an update.新型冠状病毒肺炎与心血管系统：最新进展。
Am J Med Sci. 2022 Aug;364(2):139-147. doi: 10.1016/j.amjms.2022.01.022. Epub 2022 Feb 11.
本文引用的文献
1
Atrial Fibrillation as a Predictor of Mortality in High Risk COVID-19 Patients: A Multicentre Study of 171 Patients.心房颤动是高危 COVID-19 患者死亡的预测因素：一项对 171 例患者的多中心研究。
Heart Lung Circ. 2021 Aug;30(8):1151-1156. doi: 10.1016/j.hlc.2021.02.010. Epub 2021 Mar 6.
2
Atrial arrhythmia related outcomes in critically ill COVID-19 patients.危重症 COVID-19 患者的房颤相关结局。
Pacing Clin Electrophysiol. 2021 May;44(5):814-823. doi: 10.1111/pace.14221. Epub 2021 Mar 31.
3
Atrial fibrillation and the risk of 30-day incident thromboembolic events, and mortality in adults ≥ 50 years with COVID-19.50岁及以上成人新冠病毒病患者的心房颤动与30天内发生血栓栓塞事件的风险及死亡率
J Arrhythm. 2020 Dec 11;37(1):231-237. doi: 10.1002/joa3.12458. eCollection 2021 Feb.
4
COVID-19 Coagulopathy: Current knowledge and guidelines on anticoagulation.新型冠状病毒肺炎相关凝血障碍：抗凝治疗的当前认识和指南。
Heart Lung. 2021 Mar-Apr;50(2):357-360. doi: 10.1016/j.hrtlng.2021.01.011. Epub 2021 Jan 20.
5
Incidence and treatment of arrhythmias secondary to coronavirus infection in humans: A systematic review.人类冠状病毒感染相关心律失常的发生率及治疗：系统综述。
Eur J Clin Invest. 2021 Feb;51(2):e13428. doi: 10.1111/eci.13428. Epub 2020 Nov 26.
6
Clinical characteristics and prognosis of hospitalized COVID-19 patients with incident sustained tachyarrhythmias: A multicenter observational study.多中心观察性研究：住院 COVID-19 患者新发持续性快速性心律失常的临床特征和预后。
Eur J Clin Invest. 2020 Dec;50(12):e13387. doi: 10.1111/eci.13387. Epub 2020 Sep 17.
7
Extrapulmonary manifestations of COVID-19.COVID-19 的肺外表现。
Nat Med. 2020 Jul;26(7):1017-1032. doi: 10.1038/s41591-020-0968-3. Epub 2020 Jul 10.
8
Recognizing COVID-19-related myocarditis: The possible pathophysiology and proposed guideline for diagnosis and management.识别 COVID-19 相关心肌炎：可能的病理生理学及诊断和管理建议指南。
Heart Rhythm. 2020 Sep;17(9):1463-1471. doi: 10.1016/j.hrthm.2020.05.001. Epub 2020 May 5.
9
Cardiovascular Risks in Patients with COVID-19: Potential Mechanisms and Areas of Uncertainty.COVID-19 患者的心血管风险：潜在机制和不确定领域。
Curr Cardiol Rep. 2020 Apr 29;22(5):34. doi: 10.1007/s11886-020-01293-2.
10
Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation.采用新型基于风险因素的方法对房颤患者的卒中与血栓栓塞风险进行临床分层的研究：房颤的欧洲心脏调查。
Chest. 2010 Feb;137(2):263-72. doi: 10.1378/chest.09-1584. Epub 2009 Sep 17.
Zotero 插件